Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.65 |
| ▸ | JAK1 | P23458 | 2/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1225473 | 1.00 | NR1H2 (0.65) | NR1H2JAK1JAK2GPR119NAMPT | |
| SCHEMBL903879 | 1.00 | NR1H2 (0.65) | NR1H2JAK1JAK2GPR119NAMPT | |
| SCHEMBL15755272 | 0.96 | NR1H2 (0.60) | NR1H2JAK1JAK2GPR119NAMPT | |
| SCHEMBL10093467 | 0.89 | NR1H2 (0.55) | NR1H2JAK1JAK2GPR119NAMPT | |
| SCHEMBL343549 | 0.89 | NR1H2 (0.55) | NR1H2JAK1JAK2GPR119NAMPT | |
| SCHEMBL343551 | 0.89 | NR1H2 (0.55) | NR1H2JAK1JAK2GPR119NAMPT | |
| SCHEMBL343550 | 0.89 | NR1H2 (0.55) | NR1H2JAK1JAK2GPR119NAMPT | |
| SCHEMBL445759 | 0.88 | NR1H2 (0.51) | NR1H2GPR119NAMPTUSP2SMN1; SMN2 | |
| SCHEMBL29674207 | 0.86 | NR1H2 (0.54) | NR1H2JAK1JAK2GPR119NAMPT | |
| SCHEMBL30164990 | 0.83 | NR1H2 (0.57) | NR1H2GPR119NAMPTUSP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2280003-A2 | Process for preparing receptor-type kinase modulators | Symphony Evolution, Inc. (US) | 2011-02-02 | — | — | EP | claimed |
| WO-2025133989-A1 | SMYD MODULATORS AND USES THEREOF | ALT-BIO PTE. LTD. (SG) | 2025-06-26 | — | — | WO | disclosed |
| EP-3329918-B1 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2022-05-25 | — | — | EP | disclosed |
| US-11124482-B2 | C-met modulators and methods of use | EXELIXIS, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-20210253530-A9 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC. | 2021-08-19 | — | — | US | disclosed |
| US-20200331860-A1 | C-Met Modulators and Methods of Use | EXELIXIS INC (US) | 2020-10-22 | — | — | US | disclosed |
| US-20170355678-A1 | C-Met Modulators and Methods of Use | EXELIXIS INC (US) | 2017-12-14 | — | — | US | disclosed |
| US-9796704-B2 | Substituted quinazolines as receptor-type kinase inhibitors | SYMPHONY EVOLUTION, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| EP-2409704-B1 | c-Met modulators and methods of use | EXELIXIS INC (US) | 2017-09-20 | — | — | EP | disclosed |
| US-20160185725-A1 | c-Met Modulators and Method of Use | EXELIXIS, INC. | 2016-06-30 | — | — | US | disclosed |
| EP-2210607-B1 | N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer | EXELIXIS INC (US) | 2011-08-17 | — | — | EP | disclosed |
| EP-2213661-B1 | c-Met Modulators and Methods of Use | EXELIXIS INC (US) | 2011-07-20 | — | — | EP | disclosed |
| US-7977345-B2 | c-MET modulators and method of use | EXELIXIS, INC. (US) | 2011-07-12 | — | — | US | disclosed |
| US-20110077233-A1 | C-Met Modulators and Method of Use | EXELIXIS, INC. (US) | 2011-03-31 | — | — | US | disclosed |
| EP-2280003-A2 | Process for preparing receptor-type kinase modulators | Symphony Evolution, Inc. (US) | 2011-02-02 | — | — | EP | disclosed |
| EP-2277867-A2 | Compounds, pharmaceutical compositions thereof and their use in treating cancer | Symphony Evolution, Inc. (US) | 2011-01-26 | — | — | EP | disclosed |
| EP-2213661-A1 | c-Met Modulators and Methods of Use | Exelixis Inc. (US) | 2010-08-04 | — | — | EP | disclosed |
| EP-2210607-A1 | N-[3-fluoro-4-({6-(methyloxy)-7-[(3-piperidin-1-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer | Exelixis Inc. (US) | 2010-07-28 | — | — | EP | disclosed |
| US-20090105299-A1 | c-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC (US) | 2009-04-23 | — | — | US | disclosed |
| US-20080161305-A1 | C-Met Modulators and Methods of Use | EXELIXIS, INC. (US) | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200331860-A1 | C-Met Modulators and Methods of Use | FLT4, FLT1, MET | NR1H2 3554/4885JAK1 471/4885JAK2 184/4885 |
| US-20170355678-A1 | C-Met Modulators and Methods of Use | FLT4, FLT1, MET | NR1H2 3554/4885JAK1 471/4885JAK2 184/4885 |
| US-20210253530-A9 | C-MET MODULATORS AND METHODS OF USE | FLT4, FLT1, MET | NR1H2 3554/4885JAK1 471/4885JAK2 184/4885 |
| US-20080161305-A1 | C-Met Modulators and Methods of Use | MET, HGFAC, HGF | NR1H2 4590/4885JAK1 1727/4885JAK2 656/4885 |
| US-20160185725-A1 | c-Met Modulators and Method of Use | FLT4, MET, FLT1 | NR1H2 4016/4885JAK1 383/4885JAK2 320/4885 |
| US-11124482-B2 | C-met modulators and methods of use | FLT4, FLT1, MET | NR1H2 3554/4885JAK1 471/4885JAK2 184/4885 |
| US-20090105299-A1 | c-MET MODULATORS AND METHODS OF USE | FLT4, MET, FLT1 | NR1H2 3959/4885JAK1 405/4885JAK2 321/4885 |
| US-20110077233-A1 | C-Met Modulators and Method of Use | FLT4, MET, FLT1 | NR1H2 4016/4885JAK1 383/4885JAK2 320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.